PTC is trawling for a buyer with its risky DMD drug, Reuters says

Damian Garde

PTC Therapeutics is looking to get bought, ' sources say, betting that a larger company will covet its treatment for Duchenne muscular dystrophy enough to overlook a checkered history.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS